Reply
- PMID: 29122170
- PMCID: PMC6905461
- DOI: 10.1016/j.jaip.2017.08.018
Reply
Conflict of interest statement
Conflicts of interest: W. W. Stevens has received research support from Parker B. Francis Fellowship Program, the American Partnership for Eosinophilic Disorders/American Academy of Allergy, Asthma and Immunology HOPE Pilot Grant Award, and the National Institutes of Health’s National Center for Advancing Translational Sciences, KL2TR001424. A. T. Peters has received consultancy fees from Sanofi (advisory board membership). R. P. Schleimer has received research support from the National Institutes of Health; has received consultancy fees from Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/MedImmune, Genentech, Exicure Inc., and Otsuka Inc,; and has stock in Allakos, Aurasense, BioMarck, and Exicure Inc.
Figures

Comment on
-
Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1061-1070.e3. doi: 10.1016/j.jaip.2016.12.027. Epub 2017 Mar 9. J Allergy Clin Immunol Pract. 2017. PMID: 28286156 Free PMC article.
-
Eosinophilic asthma with nasal polyposis march: Is aspirin-exacerbated respiratory disease the last station?J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1807-1808. doi: 10.1016/j.jaip.2017.07.048. J Allergy Clin Immunol Pract. 2017. PMID: 29122169 No abstract available.
Similar articles
-
Eosinophilic asthma with nasal polyposis march: Is aspirin-exacerbated respiratory disease the last station?J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1807-1808. doi: 10.1016/j.jaip.2017.07.048. J Allergy Clin Immunol Pract. 2017. PMID: 29122169 No abstract available.
-
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.J Allergy Clin Immunol Pract. 2019 Feb;7(2):589-596.e3. doi: 10.1016/j.jaip.2018.08.021. Epub 2018 Sep 5. J Allergy Clin Immunol Pract. 2019. PMID: 30193936 Clinical Trial.
-
Aspirin-induced asthma and nasal polyps.Acta Otolaryngol Suppl. 1986;430:21-7. Acta Otolaryngol Suppl. 1986. PMID: 3461681
-
Management of nasal polyps in 'aspirin sensitive asthma' triad.Curr Opin Otolaryngol Head Neck Surg. 2011 Feb;19(1):6-10. doi: 10.1097/MOO.0b013e328341e273. Curr Opin Otolaryngol Head Neck Surg. 2011. PMID: 21124222 Review.
-
Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?Laryngoscope. 2017 Apr;127(4):776-777. doi: 10.1002/lary.26377. Epub 2016 Nov 4. Laryngoscope. 2017. PMID: 27813100 Free PMC article. Review. No abstract available.
References
-
- Yılmaz İ, Türk M, Bahçecioğlu SN. Eosinophilic asthma with nasal polyposis march: is aspirin-exacerbated respiratory disease the last station? J Allergy Clin Immunol Pract 2017;5:1807–8. - PubMed
-
- Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyper-plastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005;94:652–7. - PubMed
-
- Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, et al. Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil. Laryngoscope 2013;123:E1–9. - PubMed
-
- Brescia G, Barion U, Zanotti C, Giacomelli L, Martini A, Marioni G. The prognostic role of serum eosinophil and basophil levels in sinonasal polyposis. Int Forum Allergy Rhinol 2017;7:261–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical